JP2013537426A5 - - Google Patents

Download PDF

Info

Publication number
JP2013537426A5
JP2013537426A5 JP2013524945A JP2013524945A JP2013537426A5 JP 2013537426 A5 JP2013537426 A5 JP 2013537426A5 JP 2013524945 A JP2013524945 A JP 2013524945A JP 2013524945 A JP2013524945 A JP 2013524945A JP 2013537426 A5 JP2013537426 A5 JP 2013537426A5
Authority
JP
Japan
Prior art keywords
adenovirus
cancer
item
orf3
impaired
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013524945A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013537426A (ja
JP5905460B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/048005 external-priority patent/WO2012024350A2/en
Publication of JP2013537426A publication Critical patent/JP2013537426A/ja
Publication of JP2013537426A5 publication Critical patent/JP2013537426A5/ja
Application granted granted Critical
Publication of JP5905460B2 publication Critical patent/JP5905460B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013524945A 2010-08-16 2011-08-16 抗がんアデノウイルス Active JP5905460B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37421510P 2010-08-16 2010-08-16
US61/374,215 2010-08-16
PCT/US2011/048005 WO2012024350A2 (en) 2010-08-16 2011-08-16 Anti-cancer adenoviruses

Publications (3)

Publication Number Publication Date
JP2013537426A JP2013537426A (ja) 2013-10-03
JP2013537426A5 true JP2013537426A5 (enExample) 2014-09-18
JP5905460B2 JP5905460B2 (ja) 2016-04-20

Family

ID=45605646

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013524945A Active JP5905460B2 (ja) 2010-08-16 2011-08-16 抗がんアデノウイルス

Country Status (10)

Country Link
US (1) US9187733B2 (enExample)
EP (1) EP2606137B1 (enExample)
JP (1) JP5905460B2 (enExample)
KR (1) KR101667094B1 (enExample)
CN (1) CN103180448B (enExample)
AU (1) AU2011292119B2 (enExample)
BR (1) BR112013003579A2 (enExample)
CA (1) CA2807778C (enExample)
SG (1) SG187785A1 (enExample)
WO (1) WO2012024350A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011292119B2 (en) * 2010-08-16 2015-06-11 Salk Institute For Biological Studies Anti-cancer adenoviruses
JP6170999B2 (ja) * 2012-03-13 2017-07-26 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスおよび化学二量体を用いる選択細胞の標的化
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
PL3198009T3 (pl) 2014-09-24 2022-01-24 Salk Institute For Biological Studies Onkolityczne wirusy nowotworowe i sposoby zastosowania
ES2837400T3 (es) 2015-10-05 2021-06-30 Salk Inst For Biological Studi Adenovirus sintético con tropismo para los tejidos dañados para su uso en la promoción de la reparación de heridas y regeneración tisular
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
TW201907937A (zh) 2017-05-08 2019-03-01 美商葛利史東腫瘤科技公司 阿爾法病毒新抗原載體
JP7430395B2 (ja) 2018-04-09 2024-02-13 ソーク インスティテュート フォー バイオロジカル スタディーズ 複製特質が増強された腫瘍溶解性アデノウイルス組成物
MX2021014525A (es) * 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA137094A (en) 1911-08-31 1911-11-28 Sheppe, Alice L. Cloth measuring and price calculating machine
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
ES2180258T3 (es) * 1998-07-07 2003-02-01 Transgene Sa Utilizacion de pautas de lectura abierta adenovirales de e4 para mejorar la expresion de genes.
EP1083229A1 (en) * 1999-09-10 2001-03-14 Introgene B.V. Modified adenoviral vectors for use in gene therapy
CN1293196C (zh) 2000-05-26 2007-01-03 大日本住友制药株式会社 具有副作用降低的特性的新型重组腺病毒载体
US20020106382A1 (en) * 2000-07-14 2002-08-08 Young Charles S.H. Modified adenovirus and uses thereof
US20030220284A1 (en) 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
WO2003092579A2 (en) 2002-04-29 2003-11-13 Hadasit Medical Research Services And Development Company Ltd. Compositions and methods for treating cancer with an oncolytic viral agent
EP1545627A4 (en) 2002-10-01 2006-12-27 Univ Duke TARGETED TUMOR THERAPY THROUGH THE USE OF RECOMBINANT ADENOVIRUS VECTORS FOR SELECTIVE REPLICATION IN HYPOXIC TUMOR REGIONS
US20050201978A1 (en) 2003-11-17 2005-09-15 Lipton James S. Tumor and infectious disease therapeutic compositions
KR20110081222A (ko) * 2008-09-26 2011-07-13 어번 유니버시티 비복제성 벡터화된 백신의 점막 투여에 의한 조류의 면역화
AU2011292119B2 (en) * 2010-08-16 2015-06-11 Salk Institute For Biological Studies Anti-cancer adenoviruses

Similar Documents

Publication Publication Date Title
Barkauskas et al. Cellular mechanisms of tissue fibrosis. 7. New insights into the cellular mechanisms of pulmonary fibrosis
AR090470A1 (es) Vacuna contra el virus sincicial respiratorio (rsv)
MX2024005757A (es) Virus pichinde de tres segmentos como vectores de vacunas.
BR112016020688A2 (pt) Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc)
SA520412637B1 (ar) B7 الفيروس الغدي الحال للورم المشفِّر لبروتين
JP2013530155A5 (enExample)
EA201301173A1 (ru) Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования
FR2981643B1 (fr) Procede de preparation d'un materiau composite silicium/carbone, materiau ainsi prepare, et electrode notamment electrode negative, comprenant ce materiau.
WO2015061294A3 (en) Use of sting agonists to treat chronic hepatitis b virus infection
BR112014015016A8 (pt) Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção
IN2015DN00376A (enExample)
JP2018512047A5 (enExample)
FI3581650T3 (fi) IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
BR112015008930A2 (pt) vacinas baseadas em partícula recombinante contra a infecção por citomegalovírus humano
JP2011157399A5 (enExample)
NZ628385A (en) Batches of recombinant adenovirus with altered terminal ends
BR112014028315A2 (pt) mposto, métodos para introdução de uma molécula dentro do citosol de uma célula, para obter a morte de uma célula, para expressar uma molécula antigênica ou uma parte da mesma na superfície de uma célula, e para tratamento ou prevenção de uma doença, distúrbio ou infecção em um paciente, composição farmacêutica, célula ou uma população de células, e, kit
PE20142435A1 (es) Particulas inhalables que comprenden tiotropio
MD4481B1 (ro) Herpesvirus recombinant Koi (KHV) şi vaccin pentru profilaxia bolii cauzate de KHV
EA201401353A1 (ru) Биомаркеры для определения эффективной ответной реакции на лечение пациентов с гепатоцеллюлярной карциномой (гцк)
JP2018512597A5 (enExample)
JP2013544892A5 (enExample)
EP2903632A4 (en) COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE IN DIABETES PATIENTS
Hu et al. Oncolytic viruses for the treatment of bladder cancer: advances, challenges, and prospects
JP2015044878A5 (enExample)